TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30093681

Group type: EXPERIMENTAL
Intervention: Tamibarotene (6 mg/m2 daily for 14 days every 3 months for 2 years)
Number of subjects: 269

Group type: COMPARATOR
Intervention: All-trans retinoic acid (ATRA) (45 mg/m2 daily for 14 days every 3 months for 2 years)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Tamibarotene
Number of subjects: 269

Group type: COMPARATOR
Intervention: ATRA
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Overall survival after randomization
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Late complications (secondary hematopoietic disorders, secondary malignancies, grade 3 or more late cardiac comorbidities)
Number of subjects: 269
Study: 30347030

Group type: EXPERIMENTAL
Intervention: L‐CRA plus monthly injections of intravitreal ranibizumab, 0.5 mg (combination group; n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ranibizumab alone (sham procedure plus monthly injections of intravitreal ranibizumab, 0.5 mg; n = 29)
Number of subjects: 58
Study: 27603152

Group type: EXPERIMENTAL
Intervention: HOME program (enhanced occupational therapy discharge planning intervention with pre- and postdischarge home visits)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: HOME program
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (usual care intervention with in-hospital consultation)
Number of subjects: 400
Study: 25105874

Group type: EXPERIMENTAL
Intervention: Active Body Control Program (ABC), n = 60
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 4sigma telephone coaching (4S), n = 58
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group, n = 62
Number of subjects: 184
Study: 23272061

Group type: EXPERIMENTAL
Intervention: T-cell vaccination (TCV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham injections (Control)
Number of subjects: 26
Study: 20386343

Group type: EXPERIMENTAL
Intervention: Low-dose oral estrogen (1 mg) combined with drospirenone (2 mg) for 2 years
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19117517

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 51
Study: 15996800

Group type: EXPERIMENTAL
Intervention: Isometric cervical strength measured in chronic whiplash patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Flexion/extension strength ratio
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Correlation of flexion/extension strength ratio with mean coefficient of variation
Number of subjects: 97
Study: 12645863

Group type: EXPERIMENTAL
Intervention: Danazol treatment for 12 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fertile control group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Explained infertility group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Unexplained infertility patients
Number of subjects: 67
Study: 10745187

Group type: EXPERIMENTAL
Intervention: Social problem solving measures (Problem Solving Inventory and Rusk Problem Solving Role Play Test)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Conventional neuropsychological measures (WAIS‐R/II Comprehension subtest and Wisconsin Card Sorting Test)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 34
Study: 8621010

Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) 50 mg q.i.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1447664

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: No therapy
Number of subjects: 47
Study: 3905050

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study: 31812510

Group type: EXPERIMENTAL
Intervention: Belapectin 2 mg/kg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Belapectin 8 mg/kg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Belapectin 2 mg/kg (subgroup without esophageal varices)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 30428902

Group type: COMPARATOR
Intervention: Standard care (control group, n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Online eHealth platform (online group, n = 50)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Wireless monitoring devices (device group, n = 50)
Number of subjects: 200
Study: 27834984

Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone 0.1 mg kg⁻¹
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline 0.1 mL kg⁻¹
Number of subjects: 50
Study: 24747504

Group type: EXPERIMENTAL
Intervention: Memantine hydrochloride (Memary) at a dose of 20 mg/day
Number of subjects: 702
Study: 22797514

Group type: EXPERIMENTAL
Intervention: Mydrin-P (tropicamide and phenylephrine)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Unpreserved saline (placebo)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison between Mydrin-P and saline
Number of subjects: 29
Study: 20970380

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with whole brain radiotherapy (n=154)
Number of subjects: 551

Group type: COMPARATOR
Intervention: High-dose methotrexate without whole brain radiotherapy (n=164)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with whole brain radiotherapy
Number of subjects: 551

Group type: COMPARATOR
Intervention: High-dose methotrexate without whole brain radiotherapy
Number of subjects: 551
Study: 18519285

Group type: EXPERIMENTAL
Intervention: Intermediate care at a community hospital (n=72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: General hospital care (n=70)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Intermediate care at a community hospital
Number of subjects: 142
Study: 16030104

Group type: EXPERIMENTAL
Intervention: Combination of selenium and vitamin E supplementation for 3 to 6 weeks before prostatectomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Selenium supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vitamin E supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12161049

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Transdermal hormonal replacement therapy system
Number of subjects: 46
Study: 12349828

Group type: EXPERIMENTAL
Intervention: Ad(GV)CFTR.10 administered to airways of individuals with cystic fibrosis (3 x 10(7) to 2 x 10(10) particle units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad(GV)VEGF121.10 administered to myocardium of individuals with coronary artery disease (4 x 10(8) to 4 x 10(10) particle units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad(GV)VEGF121.10 administered to lower extremity muscles of individuals with peripheral vascular disease (4 x 10(8) to 4 x 10(9.5) particle units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad(GV)CD.10 administered to skin of normal individuals (7 x 10(7) to 7 x 10(9) particle units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad(GV)CD.10 administered to airways of normal individuals (7 x 10(8) to 7 x 10(10) particle units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad(GV)CD.10 administered to liver metastasis of individuals with colon carcinoma (4 x 10(8) to 4 x 10(9) particle units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control individuals who had chest surgery and bronchoscopy, but no vector administration
Number of subjects: 0
Study: 9790340

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy and retroperitoneal soft‐tissue clearance
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 81
Study: 7500479

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 0
Study: 2136974

Group type: EXPERIMENTAL
Intervention: Anaritide (0.03, 0.06, 0.075, and 0.100 microgram/kg/min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anaritide (all doses except the highest 0.300 microgram/kg/min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anaritide (0.060, 0.075, and 0.100 microgram/kg/min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anaritide (0.300 microgram/kg/min)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 350491

Group type: EXPERIMENTAL
Intervention: 20 mg bufexamac
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40 mg triamcinolone acetonide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: bufexamac
Number of subjects: 40

Group type: COMPARATOR
Intervention: triamcinolone acetonide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: bufexamac and triamcinolone acetonide
Number of subjects: 40
Study: 6981349

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion (when platelet count fell below 20,000 per mm3)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Therapeutic platelet transfusion (only when significant bleeding occurred)
Number of subjects: 56
Study: 29436942

Group type: EXPERIMENTAL
Intervention: 6‐mm‐long implants
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal‐length implants (10 mm)
Number of subjects: 36
Study: 26902546

Group type: EXPERIMENTAL
Intervention: DTwP vaccine first
Number of subjects: 130

Group type: COMPARATOR
Intervention: Hepatitis B vaccine first
Number of subjects: 130
Study: 24314586

Group type: EXPERIMENTAL
Intervention: Fish-oil based lipid emulsion (SmofLipid®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Soybean oil based lipid emulsion (Intralipid®)
Number of subjects: 80
Study: 23136276

Group type: EXPERIMENTAL
Intervention: Integrated community case management (CMDs treating malaria and pneumonia)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Home-based management (CMDs treating only malaria)
Number of subjects: 1095
Study: 19787787

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 90
Study: 18337284

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1500 mg QD (or 750 mg if bodyweight ≤30 kg)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Penicillin V 500 mg BID (or 250 mg if bodyweight ≤20 kg)
Number of subjects: 353
Study: 16333048

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12846450

Group type: EXPERIMENTAL
Intervention: Recombinant human leptin (rL) 10 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant human leptin (rL) 10 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9869578

Group type: COMPARATOR
Intervention: Sporanox (reference)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Traconal (test)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy models based on three sampling times
Number of subjects: 18

Group type: COMPARATOR
Intervention: Three-point models developed for the reference formulation
Number of subjects: 18
Study: 8877306

Group type: EXPERIMENTAL
Intervention: Dynamic physiotherapeutic training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Static physiotherapeutic training
Number of subjects: 56
Study: 1888817

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 6130195

Group type: EXPERIMENTAL
Intervention: Flubendazole 750 mg intramuscularly once a week for 5 doses
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC) 100 mg twice daily for 14 days
Number of subjects: 19
Study: 30514114

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (36 sessions over 12 weeks, 45 minutes each session)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 20
Study: 29917064

Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg once daily
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Peficitinib 75 mg once daily
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg once daily
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Peficitinib 75 mg twice daily
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Combined peficitinib group (>=75 mg o.d.)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 27162098

Group type: EXPERIMENTAL
Intervention: Active tACS at 1 mA peak-to-peak
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tACS (Control)
Number of subjects: 0
Study: 24201090

Group type: EXPERIMENTAL
Intervention: Melbourne Infant Feeding, Activity and Nutrition Trial (InFANT) Program
Number of subjects: 542
Study: 22980173

Group type: EXPERIMENTAL
Intervention: 0.5 mg of alprazolam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19825218

Group type: EXPERIMENTAL
Intervention: Kidney beans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Groundnuts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Legumes (general)
Number of subjects: 0
Study: 19014841

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (7-14 days)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Long-course antibiotic therapy (14-42 days)
Number of subjects: 4
Study: 16149276

Group type: EXPERIMENTAL
Intervention: Early diagnostic laparoscopy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional diagnostic methods
Number of subjects: 110
Study: 11812272

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) formulation of ipratropium bromide
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dry powder inhaler (DPI) formulation of ipratropium bromide
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both MDI and DPI
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DPI
Number of subjects: 39
Study: 10473326

Group type: EXPERIMENTAL
Intervention: Standard Assessment of Personality (SAP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: International Personality Disorder Examination (IPDE)
Number of subjects: 90
Study: 8539604

Group type: EXPERIMENTAL
Intervention: Acoustically modified speech training with listening exercises and computer games for 4 weeks
Number of subjects: 0
Study: 1897766

Group type: EXPERIMENTAL
Intervention: 40 mL of 0.25% bupivacaine with epinephrine injected intrapleurally postoperatively
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20 mL of 0.5% bupivacaine with epinephrine
Number of subjects: 40
Study: 6183089

Group type: EXPERIMENTAL
Intervention: Sandoglobulin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Gamma‐Venin
Number of subjects: 14
Study: 29781941

Group type: EXPERIMENTAL
Intervention: 16-kg kettlebell snatches
Number of subjects: 10

Group type: COMPARATOR
Intervention: Graded-exercise test on a rowing ergometer
Number of subjects: 10
Study: 30563273

Group type: EXPERIMENTAL
Intervention: two servings of protein (77.2 g, 586 kcal)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: two servings of carbohydrate (126.8 g, 582 kcal)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: one serving of protein (38.6 g, 293 kcal)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: one serving of carbohydrate (63.4 g, 291 kcal)
Number of subjects: 4

Group type: COMPARATOR
Intervention: non-supplemented soldiers
Number of subjects: 4
Study: 27797709

Group type: EXPERIMENTAL
Intervention: Whey protein (2 × 28 g/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calcium caseinate (2 × 28 g/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 42
Study: 23892826

Group type: EXPERIMENTAL
Intervention: Programs led by trained American Indian community members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free pharmacotherapy, including nicotine replacement therapy (NRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nominal incentives, e.g., gift cards for groceries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally specific program components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical verification of smoking abstinence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment or delayed treatment control groups
Number of subjects: 0
Study: 23209576

Group type: EXPERIMENTAL
Intervention: Add-on ethyl-EPA supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20843217

Group type: EXPERIMENTAL
Intervention: Combination of psychosocial skills training, family psycho-education and customary pharmacotherapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Customary treatment alone
Number of subjects: 83
Study: 18434045

Group type: EXPERIMENTAL
Intervention: LST+SFP 10-14
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: LST-alone
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Higher-risk subsample (LST+SFP 10-14 or LST-alone)
Number of subjects: 1677
Study: 16435637

Group type: EXPERIMENTAL
Intervention: Positive verbal presentation (EG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral explanation (CG)
Number of subjects: 60
Study: 12811473

Group type: EXPERIMENTAL
Intervention: Milk containing 1.8 g of non‐esterified pure plant sterols/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 16
Study: 10509766

Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (0.46 g available CHO/kg body weight)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: White bread (0.46 g available CHO/kg body weight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Starch-free placebo ('normal' food regimen)
Number of subjects: 16
Study: 8941515

Group type: EXPERIMENTAL
Intervention: Low-glycogen (LG) trial
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-glycogen (HG) trial
Number of subjects: 7
Study: 1718348

Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial chemotherapy with vincristine and bleomycin for 12 days
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial chemotherapy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 222
Study: 7039757

Group type: EXPERIMENTAL
Intervention: Silicone elastomer intravenous cannula (Visis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene cannula (Cathlon)
Number of subjects: 0
Study: 28006989

Group type: EXPERIMENTAL
Intervention: Goal Management Implementation Intentions training (GMTii)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 30
Study: 30256751

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln (1.2 g HMB, 7 g L‐Arg, and 7 g L‐Gln)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (isocaloric juice)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln
Number of subjects: 61
Study: 25417170

Group type: EXPERIMENTAL
Intervention: Training + LLLT Group (TLG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 23651717

Group type: EXPERIMENTAL
Intervention: Group-based rehabilitation (12 outpatient visits over six weeks including strength and endurance exercises, education, and self-management)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual, supervised home-training
Number of subjects: 80
Study: 20959720

Group type: EXPERIMENTAL
Intervention: UAG 200 μg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: UAG 100 μg + AG 100 μg (Comb)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19536041

Group type: EXPERIMENTAL
Intervention: PCV-9 vaccination
Number of subjects: 2342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2342

Group type: COMPARATOR
Intervention: Younger siblings (non-PCV-9 vaccinated)
Number of subjects: 2342
Study: 16451435

Group type: EXPERIMENTAL
Intervention: Rotating ultrasonic insert
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard universal insert
Number of subjects: 32
Study: 15626267

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 4992

Group type: COMPARATOR
Intervention: Control (placebo or untreated)
Number of subjects: 4992
Study: 11291357

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg four times a day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 9211127

Group type: EXPERIMENTAL
Intervention: naloxone (0.8 mg i.v. bolus, followed by infusion of 1.6 mg/h for 120')
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: alpha-MSH (2.5 mg i.v. bolus)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: naloxone + alpha-MSH (2.5 mg i.v. 15' after commencement of the naloxone infusion)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GnRH (100 micrograms i.v. at time 0)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GnRH + naloxone (100 micrograms i.v. 15' after commencement of the naloxone infusion)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GnRH + alpha-MSH (100 micrograms i.v. 15' after commencement of the naloxone infusion)
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo (150 nmol/l NaCl solution)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GnRH alone (100 micrograms at time 0)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GnRH + naloxone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GnRH + alpha-MSH
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 7699834

Group type: EXPERIMENTAL
Intervention: SY5555 at a dose of 5 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SY5555 at a dose of 10 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SY5555 at a dose of 10 mg/kg (infants)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SY5555 (comparison with other antibiotics)
Number of subjects: 16
Study: 2705661

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with birch pollen allergen preparations, n = 42
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen allergen preparations, n = 14
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo oral immunotherapy, n = 16
Number of subjects: 72